Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

ALNY

+ Watchlist+ Portfolio

Alnylam Pharmaceuticals, Inc.

Regulated industryPhysical productsTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$156.50
52-Week Range
$147.58 – $479.79
Market Cap
$20.01B
P/E (TTM)
7.55
EPS (TTM)
19.80
Dividend Yield
0.00%
Advanced Metrics
Price/Book
5.55
PEG Ratio
0.21
Return on Equity
138.07%
Return on Assets
9.51%
Gross Margin
77.28%
Operating Margin
19.50%
Profit Margin
52.85%
Current Ratio
2.48
Debt/Equity
0.83
Total Debt
$3.00B
Free Cash Flow
$327.23M
Revenue Growth
16.70%
Earnings Growth
633.50%
Enterprise Value
$19.42B

Market Snapshot

About

Alnylam Pharmaceuticals, Inc. develops and commercializes RNA interference (RNAi) therapeutics for the treatment of genetically defined diseases. Headquartered in Cambridge, Massachusetts, the company pioneered the translation of RNAi biology into medicines that silence disease-causing genes. Alnylam's commercial portfolio includes ONPATTRO for hereditary transthyretin-mediated amyloidosis, GIVLAARI for acute hepatic porphyria, OXLUMO for primary hyperoxaluria type 1, and AMVUTTRA for transthyretin-mediated amyloidosis polyneuropathy. The company also markets LEQVIO, a treatment for high cholesterol, through a partnership with Novartis. Alnylam operates a robust pipeline targeting rare diseases across hepatic, cardio-renal, pulmonary, central nervous system, and ocular therapeutic areas. The company employs approximately 2,500 people globally and maintains research and manufacturing facilities in North America and Europe. In recent developments, Alnylam continues expanding its approved product indications and advancing clinical programs for conditions including Stargardt disease, Alzheimer's disease, and hypertension. The company reported total revenues exceeding $1.3 billion in 2023, driven by strong commercial product uptake. Alnylam has established itself as the leading RNAi therapeutics company, with over 20 years of experience in the field and multiple regulatory approvals demonstrating the platform's clinical validation.